Long-term clinical and radiological effectiveness and safety of ultralow doses of rituximab in rheumatoid arthritis: observational extension of the REDO trial

Long-term clinical and radiological effectiveness and safety of ultralow doses of rituximab in rheumatoid arthritis: observational extension of the REDO trial

Background The REDO trial (REtreatment with Rituximab in RhEmatoid arthritis: Disease Outcome after Dose Optimisation) showed similar disease activity for retreatment with ultralow doses (200 mg and 500 mg per 6 months) compared with standard low-dose rituximab (RTX, 1000 mg per 6 months). We perfor...

Descripció completa

Dades bibliogràfiques
Autors principals: Nathan den Broeder, Aatke van der Maas, Alfons A den Broeder, Bart JF van den Bemt, Frank HJ van den Hoogen, Yael A de Man, Marc R Kok, Lise Verhoef, Rogier Thurlings, Wilfred van der Weele
Format: Article
Idioma:English
Publicat: BMJ Publishing Group 2024-05-01
Col·lecció:RMD Open
Accés en línia:https://rmdopen.bmj.com/content/10/2/e003659.full

Internet

https://rmdopen.bmj.com/content/10/2/e003659.full

Ítems similars